| Autor: |
Escudero-Feliu J; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., García-Costela M; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., Moreno-SanJuan S; Cytometry and Microscopy Research Service, Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., Puentes-Pardo JD; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain.; Department of Pharmacology, Faculty of Pharmacy, University of Granada, E-18011 Granada, Spain., Arrabal SR; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., González-Novoa P; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., Núñez MI; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain.; Department of Radiology and Physical Medicine, Faculty of Medicine, University of Granada, E-18016 Granada, Spain.; Biopathology and Regenerative Medicine Institute (IBIMER), Center for Biomedical Research (CIBM), University of Granada, E-18100 Granada, Spain., Carazo Á; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain., Jimenez-Lopez JC; Department of Stress, Development and Plant Signalling, Estacion Experimental del Zaidin, Spanish National Research Council (CSIC), E-18008 Granada, Spain.; UWA Institute of Agriculture, The University of Western Australia, Perth, WA 6009, Australia.; UWA School of Agriculture and Environment, The University of Western Australia, Perth, WA 6009, Australia., León J; Biosanitary Research Institute of Granada (ibs.GRANADA), E-18012 Granada, Spain.; Clinical Management Unit of Digestive Disease and UNAI, San Cecilio University Hospital, E-18006 Granada, Spain. |
| Abstrakt: |
Breast cancer (BC) is the most widespread tumor in women and the second type of most common cancer worldwide. Despite all the technical and medical advances in existing therapies, between 30 and 50% of patients with BC will develop metastasis, which contributes to the failure of existing treatments. This situation urges the need to find more effective prevention and treatment strategies like the use of plant-based nutraceutical compounds. In this context, we purified three Narrow Leafed Lupin (NLL) β-conglutins isoforms using affinity-chromatography and evaluated their effectiveness in terms of viability, proliferation, apoptosis, stemness properties, and mechanism of action on both BC cell lines and a healthy one. NLL β-conglutins proteins have very promising effects at the molecular level on BC cells at very low concentrations, emerging as a potential natural cytotoxic agent and preserving the viability of healthy cells. These proteins could act through a dual mechanism involving tumorigenic and stemness-related genes such as SIRT1 and FoxO1, depending on the state of p53. More studies must be carried out to completely understand the underlying mechanisms of action of these nutraceutical compounds in BC in vitro and in vivo, and their potential use for the inhibition of other cancer cell types. |
